v3.25.1
Segment Reporting (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Segment Reporting Information [Line Items]    
Number of operating segments | segment 1  
Revenue $ 858 $ 0
Less: Significant segment expenses    
Net loss attributable to common stockholders (12,433) (12,452)
R&D    
Segment Reporting Information [Line Items]    
Revenue 858 0
Less: Significant segment expenses    
Personnel-related expenses 5,187 4,681
Clinical and preclinical expenses 4,479 4,374
Facilities-related and overhead 1,976 1,908
Professional and consulting fees 1,601 1,521
Corporate expenses 581 241
Travel and entertainment 134 150
Plus: Other segment income 667 423
Net loss attributable to common stockholders $ (12,433) $ (12,452)